Day: May 20, 2022

TORONTO, May 20, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) provides details of its 2022 annual and general meeting of shareholders (the “AGM”) to be held at Vu Restaurant located at 115 Ducksworth Street, St. John’s, Newfoundland and Labrador, A1C 1E9 at 4:00 p.m. NL Time (2:30 p.m. EST) on June 22, 2022. The AGM will be Marathon’s first held in person since 2019, and the first held by Marathon in the Province of Newfoundland and Labrador. Attendees of the meeting will be able to meet with Marathon management and board members, and receive an update on the development of the Valentine Gold Project from Matt Manson (President and CEO), Tim Williams (COO) and Julie Robertson (CFO). All registered shareholders, non-registered (or beneficial) shareholders, and duly appointed proxyholders...

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) —  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. Details for the oral presentation are as follows:Title: The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment ParadigmPresenter: Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.Date/Time: Friday, May 27, 2022 at 3:15 pm...

WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022, taking place from May 18 – 21, 2022 in Portland, Oregon. The poster presentation highlights the broad impact of KT-474 across multiple disease-relevant cell types and supports the continued development of IRAK4 degraders in patients with HS, AD and other IL-1R/TLR-driven autoimmune diseases of the skin where IRAK4 plays a central role in the pathogenesis...

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week. A webcast of the presentation will be available for on demand download beginning on Tuesday, May 24, 2022, at 7:00 AM ET through Thursday May 26, 2022, on the conference website. The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline...

– PTR-01 was well-tolerated over a four-month treatment period in RDEB patients – Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments – All patients that completed the study reported a decrease in pain over the course of treatment with PTR-01 PALO ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared...

Curtis will oversee all international operations for Mullen Automotive with a focus on existing company partnerships and new business opportunities for Mullen’s line of electric vehicles.Richard Curtis – President of International Operations Richard’s prior experience includes President of Imperium Motor Company and turnaround specialist for Lithia Motors.BREA, Calif., May 20, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today the hiring of Richard Curtis to President of International Operations for Mullen Automotive.  Prior to joining Mullen Automotive, Curtis was the president of Imperium Motor Company. Prior to Imperium Motor Company, he served as a turnaround specialist for Lithia...

Q1 financial filings expected after-market May 30, with management conference call following day TORONTO, May 20, 2022 (GLOBE NEWSWIRE) — Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products announced today that it is scheduled to file its first quarter 2022 financial statements and management’s discussion and analysis after-market on Monday, May 30, 2022. Entourage will host a conference call the following day on Tuesday, May 31, 2022 at 10 a.m. Eastern Time to review the results for the period, provide an operational update, and discuss recent milestones. Additionally, the Company reaffirmed its previously reported first quarter 2022 preliminary unaudited total revenues of $17.4 million for the period ended March 31,...

Awilco Drilling PLC’s First Quarter 2022 report will be released prior to market opening on Wednesday 25 May 2022. A digital presentation will be held the same day, Wednesday 25 May 2022, at 12:00 UK time (13:00pm CET / 07:00 EST). The presentation will be available for download on the Investor Relations section (go to “Press Releases”) at www.awilcodrilling.com prior to the meeting. There will be a Q&A session after the presentation. To join the digital meeting, please click this link or copy and paste the following address into your browser:https://eur01.safelinks.protection.outlook.com/ap/t-59584e83/?url=https%3A%2F%2Fteams.microsoft.com%2Fl%2Fmeetup-join%2F19%253ameeting_NWQ4YzNiODItNjI1Zi00MzM4LWE1NzEtMjM4MTA0NjJlMDEz%2540thread.v2%2F0%3Fcontext%3D%257b%2522Tid%2522%253a%2522c6903860-15d6-4675-a5fe-cf03764de020%2522%252c%2522Oid%2522%253a%2522b70a3a9b-a081-41f9-b2a4-3e57ef82979e%2522%252c%2522IsBroadcastMeeting%2522%253atrue%257d%26btype%3Da%26role%3Da&data=05%7C01%7Cchaavind%40awilhelmsen.no%7C68232d21f5144136953108da3a4cf38d%7C13406330ee5743ad9fa7ea6e572899d4%7C0%7C0%7C637886399426773054%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=1vTuU4SGJ1jzhuVpvhpR0P%2BFnWaoO9Z%2FwvXSgYg3kkk%3D&reserved=0 A...

HighlightsPage loading time – a key aspect of search engine optimization – now 0.6 seconds Locafy’s unique platform means latest development deployed globally in minutesPERTH, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) — Locafy Limited (NASDAQ: LCFY, LCFYW) (“Locafy” or “the Company”), has made further breakthroughs on its patented search engine optimization (SEO) technology platform that it believes will deliver even better ranking results for its global customers. Page load time is one of the key aspects of search engine optimization and Locafy believes the most important speed metric is the Time to Interactive (TTI) – this is the time it takes for a web page to be fully interactive with a consumer. In recent trials, Locafy CTO, David Penner confirmed TTI as fast as 0.6 seconds has been achieved on many Locafy published landing...